Showing results (281-290 of 427) with videos related to

Sort By:
Pageof 43
The American Journal of Gastroenterology|June 11, 2025
Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver diseaseA Sidney Barritt, Elliot B Tapper, Philip N Newsome, et al.
Nature Reviews. Gastroenterology & Hepatology|May 13, 2022
Genetics, pathobiology and therapeutic opportunities of polycystic liver diseasePaula Olaizola, Pedro M Rodrigues, Francisco J Caballero-Camino, et al.
Journal of Hepatology|May 24, 2016
Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trialHedwig M A D'Agnolo, Wietske Kievit, R Bart Takkenberg, et al.
Gastroenterology|April 20, 2010
Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKDSergio A Gradilone, Tatyana V Masyuk, Bing Q Huang, et al.
Orphanet Journal of Rare Diseases|October 24, 2020
Novel GANAB variants associated with polycystic liver diseaseLiyanne F M van de Laarschot, René H M Te Morsche, Alexander Hoischen, et al.
JAMA Network Open|August 5, 2026
Colorectal Cancer Mortality Following an Organized Fecal Immunochemical Test-Based Screening ProgramLuis Bujanda, Beatriz Val, Isabel Portillo Villares, et al.
Atherosclerosis|November 24, 2024
Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)Santiago Iturbe-Rey, Claudia Maccali, Marco Arrese, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 8, 2019
Diagnostic and prognostic biomarkers in cholangiocarcinomaRocio I R Macias, Miroslaw Kornek, Pedro M Rodrigues, et al.
Pageof 43